Bladder Cancer

Is pT0 a Reliable End Point for Biomarker Discovery for Preoperative Chemotherapy Response in Patients with Bladder Cancer? January 22, 2025

A multicenter study of perioperative and functional outcomes of open vs. robot assisted uretero-enteric reimplantation after radical cystectomy. January 22, 2025

En bloc resection of large bladder tumor: is it feasible and reasonable? January 22, 2025

Intravesical Administration of Durvalumab for High-risk Non-muscle-invasive Bladder Cancer: A Phase 2 Study by the Hellenic GU Cancer Group. January 22, 2025

Outcomes after Radical Cystectomy in Patients with Primary Versus Secondary Bladder Cancer - Expert Commentary January 21, 2025

Spatial distribution and subtype-specific expression patterns of Nectin-4 in muscle-invasive bladder cancer. January 21, 2025

Is there a role for neoadjuvant therapies followed by radical cystectomy in oligometastatic bladder cancer? January 21, 2025

Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer. January 20, 2025

Comprehensive Genetic Profile of Chinese Muscle-Invasive Bladder Cancer Cohort. January 20, 2025

Immunohistochemistry-based molecular subtypes of urothelial carcinoma derive different survival benefit from platinum chemotherapy. January 17, 2025

Validation of clinical T stages and of prognostic negative markers in patients with muscle invasive bladder cancer: data in the Swedish National Bladder Cancer Registry vs. data from a detailed research database. January 17, 2025

Transcriptome-wide association study identifies genes associated with bladder cancer risk. January 16, 2025

Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath Trial. January 16, 2025

Diagnostic Accuracy of VI-RADS for Determining Muscle Invasion - Expert Commentary January 15, 2025

New Drug Application Initiated with U.S. FDA for TAR-200, the First and Only Intravesical Drug Releasing System for Patients with BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer January 15, 2025

Point-Based Prediction Model for Bladder Cancer Risk in Diabetes: A Random Survival Forest-Guided Approach. January 15, 2025

Feasibility and Oncological Outcome of Patients Achieving Noninvasive Downstaging After Transurethral Resection of Bladder Tumor Plus Systemic Chemotherapy for Bladder Preservation Strategy in Muscle-Invasive Bladder Cancer. January 15, 2025

Immediate second resection versus restage transurethral resection of bladder tumor: A prospective randomized clinical trial (IMMERSE trial). January 15, 2025

Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group results. January 14, 2025

Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma. January 14, 2025

Page 1 of 526